Mineralys Therapeutics, Inc. (MLYS) Stock Price & Analysis

Mineralys Therapeutics, Inc. (MLYS) fell 0.21% to USD 28.21 as of September 8, 2026 at 04:23 UTC, according to Nexqual real-time market data.

MLYS last closed at USD 28.21; the session ranged USD 27.4–28.34 on volume of 643,518 shares. Market capitalization is —, with a 52-week range of USD 22.3–47.65 (NMS). Source: Nexqual, September 8, 2026 at 04:23 UTC.

Key Statistics (as of September 8, 2026 at 04:23 UTC)

Technical Analysis (MLYS)

Nexqual's technical model rates MLYS "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 04:23 UTC.

From Mineralys Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-12)

Key Strengths & Strategy (as disclosed to the SEC)

• For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our granted patents may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates.
• Drug Development Process In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (FDCA), the Public Health Service (PHS) Act, and implementing regulations.
• Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.
• As of February 26, 2026, our patent portfolio comprises 16 distinct patent families protecting our technology relating to lorundrostat and its synthetic intermediates, methods of synthesizing lorundrostat and related compounds, various formulations of lorundrostat products, as well as methods of treating diseases with lorundrostat and related compounds.

Partnerships

• We have remaining obligations to pay Tanabe commercial milestone payments of up to $155.0 million in the aggregate upon first commercial sale and upon meeting certain annual sales targets, as well as additional commercial milestone payments of up to $10.0 million for a second indication.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:23 UTC. This page is informational and not investment advice.